Thulium fiber laser vs Ho:YAG in RIRS: a prospective randomized clinical trial assessing the efficacy of lasers and different fiber diameters (150 µm and 200 µm).


Journal

World journal of urology
ISSN: 1433-8726
Titre abrégé: World J Urol
Pays: Germany
ID NLM: 8307716

Informations de publication

Date de publication:
Dec 2023
Historique:
received: 22 04 2023
accepted: 21 09 2023
medline: 4 12 2023
pubmed: 19 10 2023
entrez: 19 10 2023
Statut: ppublish

Résumé

The aims of the study: (1) to compare the Super Pulse Thulium Fiber Laser (SP TFL) and the holmium: yttrium-aluminium-garnet (Ho:YAG) lasers in retrograde intrarenal surgery (RIRS); (2) to compare the efficacy of SP TFL laser fibers of different diameters (150 μm and 200 μm). A prospective randomized single-blinded trial was conducted. Patients with stones from 10 to 20 mm were randomly assigned RIRS in three groups: (1) SP TFL (NTO IRE-Polus, Russia) with fiber diameter of 150 μm; (2) SP TFL with 200-μm fiber; and (3) Ho:YAG (Lumenis, USA) with 200-μm fiber. Ninety-six patients with kidney stones were randomized to undergo RIRS with SP TFL using a 150-μm fiber (34 patients) and a 200-μm fiber (32 patients) and RIRS with Ho:YAG (30 patients). The median laser on time (LOT) in the 200-μm SP TFL group was 9.2 (6.2-14.6) min, in 150-μm SP TFL-11.4 (7.7-14.9) min (p = 0.390), in Ho:YAG-14.1 (10.8-18.1) min (p = 0.021). The total energy consumed in 200-μm SP TFL was 8.4 (5.8-15.2) kJ; 150-μm SP TFL - 10.8 (7.3-13.5) kJ (p = 0.626) and in Ho:YAG-15.2 (11.1-25.3) kJ (p = 0.005). Irrespective of the density, RIRS with SP TFL laser has proven to be both a safe and effective procedure. Whilst the introduction of smaller fibers may have the potential to reduce the duration of surgery, SP TFL results in a reduction in the LOT and total energy for stone ablation in RIRS compared with Ho:YAG.

Identifiants

pubmed: 37855897
doi: 10.1007/s00345-023-04651-1
pii: 10.1007/s00345-023-04651-1
pmc: PMC10693522
doi:

Substances chimiques

Thulium 8RKC5ATI4P
Holmium W1XX32SQN1

Types de publication

Randomized Controlled Trial Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

3705-3711

Informations de copyright

© 2023. The Author(s).

Références

World J Urol. 2021 Dec;39(12):4459-4464
pubmed: 34392390
J Endourol. 2021 Jan;35(1):14-20
pubmed: 32689826
Urol Int. 2020;104(5-6):459-464
pubmed: 32155628
J Urol. 2023 Aug;210(2):323-330
pubmed: 37126223
Investig Clin Urol. 2016 Jul;57(4):274-9
pubmed: 27437537
Urology. 2018 Jul;117:36-40
pubmed: 29625137
World J Urol. 2021 Jun;39(6):1683-1691
pubmed: 32253581
World J Urol. 2018 Apr;36(4):529-536
pubmed: 29177820
World J Urol. 2020 Feb;38(2):497-503
pubmed: 31055626
World J Urol. 2023 Nov;41(11):2881-2888
pubmed: 36929407
World J Urol. 2021 Sep;39(9):3651-3656
pubmed: 33758959
J Clin Med. 2022 Dec 24;12(1):
pubmed: 36614950
J Clin Med. 2022 Aug 18;11(16):
pubmed: 36013067
BJU Int. 2020 Jul;126(1):159-167
pubmed: 32277557
J Biophotonics. 2019 Apr;12(4):e201800227
pubmed: 30315636
Eur Urol. 2022 Jul;82(1):73-79
pubmed: 35300888
World J Urol. 2021 Jun;39(6):1693-1698
pubmed: 32363450
J Endourol. 2021 Dec;35(S3):S14-S21
pubmed: 34910609
World J Urol. 2017 Dec;35(12):1967-1975
pubmed: 28875295
Ann Surg. 2004 Aug;240(2):205-13
pubmed: 15273542
Urol Int. 2022;106(4):404-410
pubmed: 34134117
Arab J Urol. 2019 Apr 26;17(2):138-142
pubmed: 31285926
J Endourol. 2016 Jan;30(1):49-55
pubmed: 26381037
Curr Opin Urol. 2020 Nov;30(6):853-860
pubmed: 32925311
Lasers Med Sci. 2022 Apr;37(3):2071-2078
pubmed: 34905141
World J Urol. 2022 Jun;40(6):1377-1389
pubmed: 35072738
J Endourol. 2020 Nov;34(11):1175-1179
pubmed: 32560595
J Endourol. 2018 Dec;32(12):1108-1113
pubmed: 30398369
Transl Androl Urol. 2019 Sep;8(Suppl 4):S398-S417
pubmed: 31656746

Auteurs

Mark Taratkin (M)

Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia.

Camilla Azilgareeva (C)

Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia.

Vladislav Petov (V)

Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia.

Andrey Morozov (A)

Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia.

Stanislav Ali (S)

Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia.

Diana Babaevskaya (D)

Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia.

Vincent De Coninck (V)

Department of Urology, AZ Klina, Brasschaat, Belgium.

Dmitry Korolev (D)

Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia.

Gagik Akopyan (G)

Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia.

Cesare Marco Scoffone (CM)

Department of Urology, Cottolengo Hospital, Turin, Italy.

Denis Chinenov (D)

Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia.

Alexander Androsov (A)

Sechenov University, Moscow, Russia.

Harun Fajkovic (H)

Department of Urology, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria.
Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria.

David Lifshitz (D)

Division of Urology, Rabin Medical Center, Petach Tikva, Israel.
Sackler School of Medicine, Tel-Aviv University, Tel Aviv, Israel.

Olivier Traxer (O)

GRC #20 Lithiase Urinaire, Sorbonne University, Hôpital Tenon, Paris, France.

Dmitry Enikeev (D)

Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia. dvenikeev@gmail.com.
Department of Urology, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria. dvenikeev@gmail.com.
Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria. dvenikeev@gmail.com.
Division of Urology, Rabin Medical Center, Petach Tikva, Israel. dvenikeev@gmail.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH